During liver failure, aptamer targets TNF and CRP mainly by inhibiting TNF and tracking the site of CRP secretion, thereby blocking the inflammatory process and reducing and eliminating inflammation [109, 126]. This evidence concerns the gene TNF and Hepatic failure.